Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
E

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos
By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos
0 views
December 11, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Myeloma
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With b…

Feat. E. Terpos
14:20
7th Eurasian Hematology Oncology Summit

How I Treat Newly Diagnosed MM in 2020: Is VTD Superior to VCD? Is D…

Feat. A. Maiolino
16:17
7th Eurasian Hematology Oncology Summit

VRd, KRd and IRd in R/R MM: Real World vs. Clinical Trial Data

Feat. A. Chari
15:49
7th Eurasian Hematology Oncology Summit

2020 Updates on Maintenance Therapies in MM: Should We Consider Doub…

Feat. M. Gavriatopoulou